Key result
Pyrvinium pamoate reduced scar formation and improved cardiac contractility in a mouse model of myocardial infarction by disabling cardiac fibroblast survival under glucose-deficient conditions.
Why the study?
Does pyrvinium pamoate reduce fibrosis and improve cardiac contractility in a mouse model of myocardial infarction?
Does pyrvinium pamoate reduce fibrosis and improve cardiac contractility in a mouse model of myocardial infarction?
Pyrvinium pamoate, an FDA-approved anthelmintic drug, reduces cardiac fibrosis and improves contractile function when administered after myocardial infarction in mice, suggesting potential for repurposing in ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for pyrvinium pamoate post-MI; human trials needed before any clinical consideration.
Metabolic adaptation to limited supplies of oxygen and nutrients plays a pivotal role in health and disease. Heart attack results from insufficient delivery of oxygen and nutrients to the heart, where cardiomyocytes die and cardiac fibroblasts proliferate--the latter causing scar formation, which impedes regeneration and impairs contractility of the heart. We postulated that cardiac fibroblasts survive metabolic stress by adapting their intracellular metabolism to low oxygen and nutrients, and impeding this metabolic adaptation would thwart their survival and facilitate the repair of scarred heart. Herein, we show that an anthelmintic drug, Pyrvinium pamoate, which has been previously shown to compromise cancer cell survival under glucose starvation condition, also disables cardiac fibroblast survival specifically under glucose deficient condition. Furthermore, Pyrvinium pamoate reduces scar formation and improves cardiac contractility in a mouse model of myocardial infarction. As Pyrvinium pamoate is an FDA-approved drug, our results suggest a therapeutic use of this or other related drugs to repair scarred heart and possibly other organs.
No takes yet. Share an insight, caveat, or question.
Murakoshi et al. (2013) studied Myocardial Infarction. Pyrvinium pamoate vs. Vehicle (4% DMSO in saline) was evaluated on Cardiac fibrosis and left ventricular ejection fraction. Pyrvinium pamoate reduced scar formation and improved cardiac contractility in a mouse model of myocardial infarction by disabling cardiac fibroblast survival under glucose-deficient conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: